Trials / Completed
CompletedNCT03196206
Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of BMS- 986177 in Participants With Normal Renal Function and Participants With Moderate and Severe Renal Impairment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
Assess the pharmacokinetics, safety, and tolerability of a single dose of BMS-986177 in participants with normal renal function and moderate to severe renal impairment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986177 | Oral Suspension |
Timeline
- Start date
- 2017-07-13
- Primary completion
- 2018-03-04
- Completion
- 2018-03-04
- First posted
- 2017-06-22
- Last updated
- 2022-06-10
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03196206. Inclusion in this directory is not an endorsement.